Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of Guardant Health stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $130.19, for a total transaction of $15,102.04. Following the completion of the sale, the director owned 8,796 shares of the company’s stock, valued at $1,145,151.24. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $95.96, for a total transaction of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total value of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32.

Guardant Health Price Performance

NASDAQ GH opened at $127.34 on Wednesday. The company has a fifty day moving average of $104.90 and a 200 day moving average of $102.36. The company has a market capitalization of $16.89 billion, a PE ratio of -37.56 and a beta of 1.61. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $135.00.

Wall Street Analyst Weigh In

Several brokerages have issued reports on GH. Leerink Partners lifted their target price on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. Wells Fargo & Company raised their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Canaccord Genuity Group boosted their target price on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Guggenheim lowered Guardant Health from a “buy” rating to a “buy” rating in a research report on Thursday, May 28th. Finally, BTIG Research set a $160.00 price target on Guardant Health and gave the stock a “buy” rating in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $141.95.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GH. AQR Capital Management LLC raised its holdings in shares of Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after buying an additional 25,831 shares during the last quarter. Empowered Funds LLC acquired a new stake in Guardant Health in the first quarter valued at $274,000. Sei Investments Co. grew its holdings in Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock valued at $4,023,000 after buying an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after purchasing an additional 54,284 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after acquiring an additional 40,209 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.